Summary
- Checkmate Pharmaceuticals has proposed terms for a $75 million U.S. IPO.
- The firm is developing treatments for melanoma and head and neck squamous cell carcinoma.
- CMPI has achieved promising trial results in various treatment regimens and the IPO appears reasonably priced, so may be worth a close look for patient life science investors.
- Looking for more stock ideas like this one? Get them exclusively at IPO Edge. Get started today »
Quick Take
Checkmate Pharmaceuticals (CMPI) intends to raise $75 million from the sale of its common stock stock in an IPO, according to an amended registration statement.
The company is advancing a biologic particle treatment for melanomas and head & neck squamous cell carcinomas.
CMPI’s pipeline is quite promising and the IPO is not overpriced, so for life science investors with a patient hold time frame, the IPO may be worth considering.
Company & Technology
Cambridge, Massachusetts-based Checkmate was founded to develop its CMP-001 candidate, a Toll-like receptor 9, TLR9 'agonist delivered as a biologic virus-like particle, or VLP.'
Management is headed by Barry Labinger, who has been with the firm since December 2018 and was previously president and CEO of Biothera Pharmaceuticals, a clinical stage cancer immunotherapy company.
Below is a brief overview video of skin cancers:
